A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity

• DOI: 10.1038/s41467-023-44067-4
• Publication Date: 2023-12-14T04:22:54Z
• Authors: Linong Ji; Hongwei Jiang; Zhifeng Cheng; Wei Qiu; Lin Liao; Yawei Zhang; Xiaoli Li; Shuguang Pang; Lihui Zhang; Liming Chen; Tao Yang; Yan Li; Shen Qu; Jie Wen; Jieyu Gu; Huan Deng; Yanqi Wang; Li Li; Han Han-Zhang; Qingyang Ma; Lei Qian
• Keywords: Adult; Treatment Outcome; Diabetes Mellitus, Type 2; Double-Blind Method; Glucagon-Like Peptide 1; Science; Q; Body Weight; Humans; Hypoglycemic Agents; Obesity; Overweight; Article

Mazdutide is a once-weekly glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist. We evaluated the efficacy safety of 24-week treatment mazdutide up to 6 mg in Chinese overweight adults or with obesity, as an interim analysis randomised, two-part (low doses high dose 9 mg), double-blind, placebo-controlled phase 2 trial (ClinicalTrials.gov, NCT04904913). Overweight (body-mass index [BMI] ≥24 kg/m